Virtus ETF Advisers LLC Makes New $1.29 Million Investment in Insulet Co. (NASDAQ:PODD)

Virtus ETF Advisers LLC acquired a new stake in Insulet Co. (NASDAQ:PODD - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,935 shares of the medical instruments supplier's stock, valued at approximately $1,288,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the 4th quarter valued at $36,000. SRS Capital Advisors Inc. increased its stake in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in Insulet in the 4th quarter worth about $57,000. Assetmark Inc. boosted its position in Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 246 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Insulet by 117.3% in the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock valued at $72,000 after buying an additional 149 shares in the last quarter.

Insulet Trading Down 0.1 %

NASDAQ:PODD traded down $0.21 on Thursday, reaching $252.08. The company's stock had a trading volume of 175,510 shares, compared to its average volume of 714,050. The firm has a market cap of $17.70 billion, a price-to-earnings ratio of 43.31, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The stock has a 50 day moving average price of $258.37 and a 200 day moving average price of $261.95.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. On average, equities analysts anticipate that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.47% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on PODD. TD Cowen upped their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Royal Bank of Canada began coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target on the stock. Piper Sandler increased their target price on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Raymond James reiterated an "outperform" rating and set a $328.00 price target (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Canaccord Genuity Group raised their price objective on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a report on Friday, February 21st. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $293.94.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.